Press Release


Imaging3 Announces Formation of a Scientific Advisory Board

Dr. E. Brooke Spencer is announced as the first member of the Imaging3 SAB

Burbank, January 18, 2018: Imaging3, Inc. (OTCQB: IGNG), a development stage company targeting disruptive technologies in the medical imaging industry, announced today the formation of a Scientific Advisory Board (SAB) to aid in the development of its lead product, the Dominion SmartScan™. The first member of the SAB is Dr. E. Brooke Spencer. “The formation of a Scientific Advisory Board is an important step for our company, in order to gain timely insights from industry leaders about how the Dominion can help patients and healthcare professionals. Dr. Spencer has been an advisor to multiple technology companies and operates her own practice. Her impressive background and extensive experience in radiology provide us key insights to patient and practitioner experience.” Said CEO John Hollister, “We are excited to be working with her at this stage of development.”

Dr. E. Brooke Spencer, board certified in radiology, is the medical director and CEO of the Minimally Invasive Procedure Specialists and the Interventional Institute of Colorado in South Denver. She has served as the chairman of Radiology and Interventional Radiology at Littleton Adventist Hospital since 2013. Dr. Spencer is a pioneer in the treatment of deep vein thrombosis and chronic venous occlusions. She has extensive experience in treating varicose veins and is known nationwide for her work with chronic venous reconstruction. Dr. Spencer has conducted or participated in many clinical studies and has numerous publications. Additionally, she has served on several corporate boards and has been an advisor to other public and private companies. Dr. Spencer received her BA Cum laude with highest honors from Dartmouth College, MD from the University of Vermont, an internship in general surgery at University of North Carolina, residency in diagnostic radiology at Duke University and a fellowship in interventional radiology at Washington University in St. Louis.

Dr. Spencer added, “The Dominion looks like it has the potential to really impact the role of radiology in helping improve healthcare. I’m excited about working to help the company bring their technology to the forefront of medical imaging. ”

About Imaging3 Inc.

Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology, called the Dominion SmartScan™, that will produce 3D x-ray images, virtually in real time. The SmartScan technology has the potential to allow healthcare professionals to perform diagnostic and therapeutic procedures more quickly and accurately, resulting in higher throughput for the clinicians and fewer safety risks for the patient. In addition, Imaging3’s technology exposes patients to significantly less harmful radiation than current imaging technologies such as CT scans, which the company believes will allow scans to be used in many settings where there are concerns about radiation exposure. The technology also allows for greater portability, easier installation, and a significantly reduced cost burden for the healthcare system overall. Imaging3 is planning to submit a 510K application to the FDA during 2018 in order to gain marketing authorization for the SmartScan technology.

Visit the company’s website at for detailed information about the company’s technology.

Safe Harbor Statement

Imaging3 cautions you that any statement included in this press release that is not a description of historical facts is a forward-looking statement. Many of these forward-looking statements contain the words "anticipate," "believe," "estimate," "may" "intend," "expect" and similar expressions. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the company and are subject to a number of risks and uncertainties inherent in the Imaging3’s business, including, without limitation: the company may not ever obtain FDA approval for any of its devices; the company may not be able to secure the funds necessary to support its product development plans; and the company may not ever achieve the market success to sustain a profitable business. In addition, there are risks and uncertainties related to economic recession or terrorist actions, competition from much larger imaging companies, technological obsolescence, unexpected costs and delays, potential product liability claims, and many other factors. More detailed information about Imaging3 and the risk factors that may affect the realization of forward-looking statements is set forth in the company’s filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q. Such documents may be read free of charge on the SEC’s website at You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Imaging3 undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Investor Relations Contact:

John Hollister
Chief Executive Officer